Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 7,259 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Michael Chi sold 7,259 shares of the company's stock in a transaction on Friday, January 10th. The shares were sold at an average price of $24.07, for a total transaction of $174,724.13. Following the completion of the sale, the insider now directly owns 193,601 shares in the company, valued at approximately $4,659,976.07. This represents a 3.61 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Michael Chi also recently made the following trade(s):

• On Tuesday, December 24th, Michael Chi sold 17,303 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.97, for a total transaction of $483,964.91.
• On Thursday, December 19th, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The stock was sold at an average price of $26.00, for a total value of $195,000.00.
• On Tuesday, December 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The stock was sold at an average price of $32.25, for a total value of $234,102.75.
• On Monday, December 2nd, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The stock was sold at an average price of $33.56, for a total value of $68,932.24.
• On Friday, October 25th, Michael Chi sold 17,304 shares of Hims & Hers Health stock. The stock was sold at an average price of $22.00, for a total value of $380,688.00.
• On Monday, October 21st, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The shares were sold at an average price of $22.20, for a total value of $166,500.00.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS traded up $0.29 on Tuesday, reaching $26.19. The company's stock had a trading volume of 7,147,952 shares, compared to its average volume of 9,539,847. Hims & Hers Health, Inc. has a 52-week low of $8.14 and a 52-week high of $35.02. The stock's 50-day moving average is $27.31 and its two-hundred day moving average is $21.68. The stock has a market capitalization of $5.72 billion, a P/E ratio of 59.52 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same period in the previous year, the business posted ($0.04) earnings per share. The business's revenue was up 77.1% compared to the same quarter last year. Equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Needham & Company LLC raised their price target on Hims & Hers Health from $28.00 to $31.00 and gave the company a "buy" rating in a report on Monday, January 6th. Bank of America cut Hims & Hers Health from a "buy" rating to an "underperform" rating and decreased their price target for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Piper Sandler raised their price target on Hims & Hers Health from $21.00 to $24.00 and gave the company a "neutral" rating in a report on Monday, January 6th. Canaccord Genuity Group raised their price target on Hims & Hers Health from $28.00 to $38.00 and gave the company a "buy" rating in a report on Monday, December 2nd. Finally, TD Cowen reaffirmed a "buy" rating and issued a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $25.13.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. CHURCHILL MANAGEMENT Corp acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at approximately $445,000. Cadent Capital Advisors LLC grew its position in shares of Hims & Hers Health by 1.5% in the fourth quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company's stock valued at $1,745,000 after purchasing an additional 1,060 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Hims & Hers Health by 2,173.7% in the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company's stock valued at $54,000 after purchasing an additional 2,152 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of Hims & Hers Health by 102.0% in the third quarter. Principal Financial Group Inc. now owns 290,414 shares of the company's stock valued at $5,349,000 after purchasing an additional 146,621 shares during the last quarter. Finally, Sanctuary Advisors LLC grew its position in shares of Hims & Hers Health by 26.8% in the third quarter. Sanctuary Advisors LLC now owns 26,057 shares of the company's stock valued at $480,000 after purchasing an additional 5,505 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.